Maksumova E L, Muzychenko A P, Sokolova L V, Zheleznova E V
Ter Arkh. 1996;68(10):72-4.
Depakin syrup was given for several weeks in initial dose 300 mg/day with graded increase of the dose to 1200 mg/day to 11 patients aged 15-39 suffering from epilepsy and residual-organic affection of CNS with epileptic syndrome. A complete or partial discontinuation of the fits was achieved in 82% of the patients, primarily in those with partial and primary-generalized fits, partial fits with secondary generalization. It is concluded that depakin syrup treatment is justified in management of epilepsy, especially in the treatment-resistant cases.
德巴金糖浆给予11名年龄在15至39岁、患有癫痫以及中枢神经系统残留器质性病变并伴有癫痫综合征的患者，初始剂量为300毫克/天，持续数周，剂量逐步增加至1200毫克/天。82%的患者实现了癫痫发作完全或部分停止，主要是部分性发作和原发性全身性发作、部分性发作继发全身性发作的患者。结论是，德巴金糖浆治疗在癫痫管理中是合理的，尤其是在难治性病例的治疗中。
